Clinical Trial Update: PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating the use of a PD-1 inhibitor in combination with bevacizumab and FOLFIRI for second-line advanced colorectal cancer with MSI-H.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI regimen (irinotecan + leucovorin + 5-fluorouracil)
• PD-1 inhibitor

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: MSI-H Advanced Colorectal Cancer | Phase 2 | Status: UNKNOWN